Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean "real-life" experience

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 1, 2012, Pages 77-82

  Tzortzaki, Eleni G ^a   Georgiou, Andreas ^b   Kampas, Dimitrios ^a   Lemessios, Marinos ^b   Markatos, Miltiadis ^c   Adamidi, Tonia ^b   Samara, Katerina ^a   Skoula, Georgia ^a   Damianaki, Aggeliki ^d   Schiza, Sophia ^a   Tzanakis, Nikos ^a   Siafakas, Nikolaos M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b General Hospital of Nicosia   (Cyprus)

^c Respiratory Outpatient Clinic   (Greece)

^d Chania General Hospital St George   (Greece)

Author keywords

Allergy; Anti IgE; Asthma; Efficacy; Immunoglobulin E; Severe asthma; Therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; THEOPHYLLINE; THEOPHYLLINE DERIVATIVE;

ADD ON THERAPY; ADULT; ALLERGIC ASTHMA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CYPRUS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDITERRANEAN SEA; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SPIROMETRY; STEROID THERAPY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; COHORT STUDIES; DATA COLLECTION; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERSENSITIVITY; LONG-TERM CARE; MALE; MEDITERRANEAN REGION; MIDDLE AGED; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84856773097     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.11.004     Document Type: Article

References (24)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2008 update. Publication No. 02-3659: 1-116. NHLBI/WHO workshop report. Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute, 2008. http://www.ginasthma.com.
2. Bel E.H., Sousa A., Fleming L., Bush A., Chung K.F., Versnel J., et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011 Oct, 66(10):910-917. Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation.
3. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. JAllergy Clin Immunol 2001, 108:184-190.
4. Buhl R., Soler M., Matz J., Townley R., O'Brien J., Noga O., et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002, 20:73-78.
5. Ayres J.G., Higgins B., Chilvers E.R., Ayre G., Blogg M., Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to severe) allergic asthma. Allergy 2004, 59:701-708.
6. Strunk R.C., Bloomberg G.R. Omalizumab for asthma. NEngl J Med 2006, 354(25):2689-2695.
7. Holgate S.T., Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008, 8(3):218-230.
8. Holgate S.T., Chuchalin A.G., Hebert J., Lötvall J., Persson G.B., Chung K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632-638.
9. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
10. Lanier B.Q., Corren J., Lumry W., Liu J., Fowler-Taylor A., Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003, 91:154-159.
11. Soler M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261.
12. Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004, 59:709-717.
13. Bousquet J., Wenzel S., Holgate S., Lumry W., Freeman P., Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004, 125:1378-1386.
14. European Medicines Agency EMEA/493707/2009 Xolair. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xolair/H-606-PI-en.pdf.
15. Nathan R.A., Sorkness C.A., Kosinski M., Schatz M., Li J.T., Marcus P., et al. Development of the asthma control test: a survey for assessing asthma control. JAllergy Clin Immunol 2004, 113:59-65.
16. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., Ren S., et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003, 19:491e8.
17. Molimard M., de Blay F., Didier A., Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008 Jan, 102(1):71-76.
18. Korn S., Thielen A., Seyfried S., Taube C., Kornmann O., Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009 Nov, 103(11):1725-1731.
19. Brusselle G., Michils A., Louis R., Dupont L., Van de Maele B., Delobbe A., et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009 Nov, 103(11):1633-1642.
20. Cazzola M., Camiciottoli G., Bonavia M., Gulotta C., Ravazzi A., Alessandrini A., et al. Italian real-life experience of omalizumab. Respir Med 2010 Oct, 104(10):1410-1416.
21. Molimard M., Buhl R., Niven R., Le Gros V., Thielen A., Thirlwell J., et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med 2010 Sep, 104(9):1381-1385.
22. Braunstahl G.J., Leo J., Thirlwell J., Peachey G., Maykut R. Uncontrolled persistent allergic asthma in practice: experience registry baseline characteristics. Curr Med Res Opin 2011 Apr, 27(4):761-767.
23. Schumann C., Kropf C., Wibmer T., Rüdiger S., Stoiber K.M., Thielen A., et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2011 Jul 8, [Epub ahead of print]. 10.1111/j.1752-699X.2011.00263.x.
24. Pace E., Ferraro M., Bruno A., Chiappara G., Bousquet J., Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. JAsthma 2011 May, 48(4):387-392.